Delivery of polymeric nanostars for molecular imaging and endoradiotherapy through the enhanced permeability and retention (EPR) effect.
Animals
Cell Line, Tumor
Colonic Neoplasms
/ blood supply
Humans
Mice
Mice, Inbred BALB C
Mice, Nude
Molecular Imaging
/ methods
Nanoparticles
/ administration & dosage
Permeability
Polymers
/ chemistry
Positron-Emission Tomography
/ methods
Radiopharmaceuticals
/ pharmacokinetics
Theranostic Nanomedicine
/ methods
Tissue Distribution
Xenograft Model Antitumor Assays
EPR effect
imaging
nanoparticle
star polymer
therapy
Journal
Theranostics
ISSN: 1838-7640
Titre abrégé: Theranostics
Pays: Australia
ID NLM: 101552395
Informations de publication
Date de publication:
2020
2020
Historique:
received:
17
05
2019
accepted:
04
10
2019
entrez:
7
1
2020
pubmed:
7
1
2020
medline:
22
4
2021
Statut:
epublish
Résumé
Expression levels of biomarkers are generally unknown at initial diagnosis. The development of theranostic probes that do not rely on biomarker availability would expand therapy options for cancer patients, improve patient selection for nanomedicine and facilitate treatment of inoperable patients or patients with acquired therapy resistance. Herein, we report the development of star polymers, also known as nanostars, that allow for molecular imaging and/or endoradiotherapy based on passive targeting
Identifiants
pubmed: 31903138
doi: 10.7150/thno.36777
pii: thnov10p0567
pmc: PMC6929988
doi:
Substances chimiques
Polymers
0
Radiopharmaceuticals
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
567-584Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : R35 CA232130
Pays : United States
Informations de copyright
© The author(s).
Déclaration de conflit d'intérêts
Competing Interests: The authors have declared that no competing interest exists.
Références
MAbs. 2009 May-Jun;1(3):222-9
pubmed: 20065642
Bioeng Transl Med. 2016 Jun 03;1(1):10-29
pubmed: 29313004
Chem Rev. 2016 Jun 22;116(12):6743-836
pubmed: 27299693
Adv Healthc Mater. 2015 Jan 7;4(1):148-56
pubmed: 24985790
Curr Top Med Chem. 2010;10(12):1227-36
pubmed: 20388106
Chemistry. 2015 Sep 28;21(40):13950-60
pubmed: 26376329
Invest Radiol. 2005 Nov;40(11):715-24
pubmed: 16230904
Theranostics. 2016 Sep 9;6(12):2039-2051
pubmed: 27698939
Theranostics. 2013 Dec 11;4(1):81-9
pubmed: 24396516
Expert Opin Drug Discov. 2018 Aug;13(8):685-690
pubmed: 29792354
Molecules. 2013 Aug 05;18(8):9352-81
pubmed: 23921796
Drug Resist Updat. 2017 Jan;30:48-62
pubmed: 28363335
Nat Rev Cancer. 2017 Apr;17(4):223-238
pubmed: 28233803
Nat Rev Cancer. 2015 Jun;15(6):347-60
pubmed: 25998714
J Control Release. 2000 Mar 1;65(1-2):271-84
pubmed: 10699287
Ther Adv Med Oncol. 2012 Sep;4(5):271-9
pubmed: 22942909
Nano Lett. 2014 Feb 12;14(2):972-81
pubmed: 24422585
Eur J Hybrid Imaging. 2018;2(1):12
pubmed: 29998214
Mol Cancer Ther. 2017 Jan;16(1):124-133
pubmed: 28062708
Chem Rev. 1999 Sep 8;99(9):2293-352
pubmed: 11749483
Chem Rev. 2009 Nov;109(11):5402-36
pubmed: 19764725
Contrast Media Mol Imaging. 2006 May-Jun;1(3):128-37
pubmed: 17193689
Nat Rev Mater. 2017;2:
pubmed: 29075517
Nanomedicine (Lond). 2011 Jun;6(4):715-28
pubmed: 21718180
BMC Cancer. 2018 May 4;18(1):527
pubmed: 29728089
Semin Nucl Med. 2018 Jul;48(4):332-347
pubmed: 29852943
J Immunol. 2015 Aug 15;195(4):1341-9
pubmed: 26254266
Theranostics. 2018 Jan 1;8(2):369-383
pubmed: 29290814
Int J Radiat Oncol Biol Phys. 1991 May 15;21(1):109-22
pubmed: 2032882
Clin Cancer Res. 2019 Jan 1;25(1):166-176
pubmed: 30228208
Nucl Med Biol. 2009 Oct;36(7):729-39
pubmed: 19720285
J Nucl Med. 2017 Nov;58(11):1735-1742
pubmed: 28705917
J Nucl Med. 2005 Jun;46(6):1023-7
pubmed: 15937315
Theranostics. 2019 Mar 16;9(7):1893-1908
pubmed: 31037146
ACS Nano. 2017 Oct 24;11(10):9594-9613
pubmed: 28926225
Contrast Media Mol Imaging. 2009 Mar-Apr;4(2):89-100
pubmed: 19177472
Chem Commun (Camb). 2018 Mar 8;54(21):2599-2602
pubmed: 29388990
ACS Nano. 2015 Jul 28;9(7):6655-74
pubmed: 26149184
Inorg Chem. 2003 Jun 30;42(13):3972-4
pubmed: 12817950
Nat Rev Cancer. 2006 Sep;6(9):688-701
pubmed: 16900224